BioCentury
ARTICLE | Clinical News

NanoBio preclinical data

September 5, 2011 7:00 AM UTC

In mice, vaccination with NanoBio's intranasal nanoemulsion-adjuvanted inactivated respiratory syncytial virus (RSV) vaccine significantly increased levels of RSV-specific immunoglobulin A (IgA), IgG2a and IgG1 antibodies at week 8 vs. unvaccinated mice (p<0.01 for all), but not IgE. Vaccinated mice exhibited increased protection against subsequent live viral challenge, decreased mucus production and increased viral clearance. Data were published in PLoS One. ...